90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years

Radioimmunotherapy (RIT) after an induction phase with conventional chemoimmunotherapy became an attractive strategy of consolidation for patients with advanced follicular lymphoma: in particular, in many studies RIT was represented by yttrium‐90‐ibritumomab tiuxetan ((90)Y‐IT). Independently by the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Med
Asıl Yazarlar: Casadei, Beatrice, Pellegrini, Cinzia, Pulsoni, Alessandro, Annechini, Giorgia, De Renzo, Amalia, Stefoni, Vittorio, Broccoli, Alessandro, Gandolfi, Letizia, Quirini, Federica, Tonialini, Lorenzo, Morigi, Alice, Argnani, Lisa, Zinzani, Pier Luigi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2016
Konular:
Clinical Cancer Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924367/
https://ncbi.nlm.nih.gov/pubmed/26990782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.684
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller